Advanced searches left 3/3

Carcinoma neoadjuvant - Crossref

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas

OBJECT Choroid plexus carcinomas are rare brain tumors that result from the ventricular choroid plexus. They account for 2%u20134% of all pediatric brain tumors and are most common in young children. Multiple blood losses in small children are not unusual, often requiring the neurosurgeon to abort the procedure and leaving residual tumors. specimens obtained during a second intervention reveal reduced vascularity and fibrotic changes in tumor tissue, according to histological examination. This empirical result led to the development of neoadjuvant chemotherapy at the Hospital for Sick Children in Toronto to reduce blood loss and maximize cytoreduction. During CPC surgery, the authors undertook this research to determine the potentially beneficial effects of neoadjuvant chemotherapy on blood loss during CPC surgery. METHODS are derived from this retrospective cohort study The demographic, medical, and treatment characteristics of 22 consecutive patients with CPC are reported in this retrospective cohort analysis. Special attention was paid to the effects of neoadjuvant chemotherapy on the extent of resection and intraoperative blood loss. RESULTS Ten patients did not receive neoadjuvant chemotherapy, and 12 were treated with 2 u20135 cycles of ICE chemotherapy in a neoadjuvant fashion. The 22 participants in the study underwent a total of 37 tumor resection surgeries. Mean blood loss in the neoadjuvant chemotherapy group was 22% of total estimated blood volume, compared to 96% in patients with no preoperative chemotherapy. CONCLUSIONS With a dramatic positive effect on overall longevity, a children with CPC are children with CPC and the use of neoadjuvant chemotherapy reduces intraoperative blood loss and increases the degree of resection.

Source link: https://doi.org/10.3171/2014.12.peds14372


Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy

Background & Objectives: After neoadjuvant chemoradiotherapy, the primary objective of this research was to determine whether circumferential resection margin status has an effect on survival and recurrence of esophageal squamous cell carcinoma. Methods We screened patients with esophageal squamous cell carcinoma who underwent esophagectomy from January 2017 to December 2019. Using a restricted cubic spline curve, the most appropriate CRM cut point was determined. A CRM with a 1 mm or less CRM had improved overall longevity, longer disease-free survival, and less recurrence. We investigated the connection between CRM and the hazard ratio of survival and found the optimal cut point at 1 mm. Conclusions: A CRM with a 1 mm or less can survive and less recurrence than a CRM with improved longevity and less recurrence. After neoadjuvant therapy, a more radical resection with solid CRM may have a more effective outcome in patients with esophageal squamous cell carcinoma after neoadjuvant therapy.

Source link: https://doi.org/10.3389/fonc.2022.965255


The safety of neoadjuvant chemotherapy combined with non-tube nofasting fast-track surgery for esophageal carcinoma

McKeown minimally invasive esophagectomy was safe and effective when combined with neoadjuvant chemotherapy for McKeown's non-tube no fasting fast-track surgery. Summary of Background Data Our non-tube no-fasting fast-track surgery was safe and efficient for primary surgery esophageal cancer patients. Methods We retrospectively evaluated consecutive patients who underwent non-tube no fasting and McKeown minimally invasive procedures. Figures Between 01/2014 and December 31, 2017, there have been hundreds and eighty two patients underwent MIE with total two-field lymphadenectomy under non-tube no fasting fast-track surgery. To compare NAC patients with 62 matched patients from each group, Prosperity score matching was used to compare NAC patients with 62 matched patients from each group. The NAC group had the same average postoperative hospitalization duration as the primary surgical center, and had the same median hospitalization duration. Conclusions After McKeown MIE, the patients receiving NAC as well as a no-tube no fasting no fasting u201d FTS had a similar incidence of postoperative complications as those without NAC.

Source link: https://doi.org/10.3389/fonc.2022.906439


Clinical outcomes of neoadjuvant therapy followed by selective inguinal lymph node dissection and total mesorectal excision for metastasised rectal or anal canal adenocarcinoma

This paper was designed to clarify the clinical relevance of neoadjuvant therapy, selective inguinal lymph node dissection, and total mesorectal excision for rectal or anal canal cancer with clinically suspicious ILNM. This report included 15 patients who underwent neoadjuvant therapy and curative resection for rectal or anal canal adenocarcinoma with clinically diagnosed ILNM between 2005 and 2019 at a single facility, according to this source. Prior to neoadjuvant therapy, Inguinal lymph node dissection was selectively performed on the side of suspected metastasis. On preoperative FDG-positron emission tomography scan, six patients had negative fluorodeoxyglucose accumulation in inguinal lymph nodes, and their inguinal lymph nodes were also pathologically negative for metastasis. Four out of the nine patients with positive FDG levels had pathologically elevated inguinal lymph nodes, four of whom had pathologically positive inguinal lymph nodes. Seven patients were diagnosed with inguinal seroma postoperatively.

Source link: https://doi.org/10.21203/rs.3.rs-1997231/v1


Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma

Patients with locally advanced esophageal squamous cell carcinoma have been treated with Neoadjuvant chemoradiotherapy. After neoadjuvant therapy on patient outcomes, patient outcomes are uncertain, as well as the optimal dose of radiation therapy and the effects of lymphadenectomy. Patients with cancer-free survival, disease-free survival, and perioperative outcomes were compared between patients who received radiation doses of 45. 0 Gy and 50. 4 Gy. Based on the number of lymph nodes removed by lymph node dissection, a subgroup analysis was conducted. In 3-year OS and DFS comparisons between the PF4500 and PF5040 groups, there were no significant differences.

Source link: https://doi.org/10.3390/jcm11175059


Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma

As shown by the esophageal squamous cell carcinoma treatment guidelines, Neoadjuvant chemoradiotherapy in combination with surgery prolongs survival relative to surgery alone. However, among patients, the benefits of neo-CRT are not similar. Hence, the identification of ESCC may be crucial for the treatment of ESCC. The GSE45670 research showed differentially expressed genes between responsive and resistant samples. To determine the genes, the genes were used in the TCGA cohort for EMT score model design. These 10 genes were comprised of six risky genes and four protective genes. An EMT score model based on the lasso test and univariate Cox regression was developed. Patients with a high EMT score have a worse prognosis. These genes were also expressed in responsive and resistant patients, and they were able to distinguishing resistant and responsive patients more accurately than those that were not.

Source link: https://doi.org/10.1155/2022/3534433


Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients

Programed cell death 1 inhibitors' potential role in primary surgical care of HNSCC and their effects on surgical outcomes are poorly understood, according to the prospective neoadjuvant role. Neoadjuvant pembrolizumab was the cause of postoperative adverse events in treatment-naive patients with advanced oral cavity cancer receiving neoadjuvant pembrolizumab in comparison to matched controls, according to a window-of-opportunity multi-institutional clinical trial evaluating neoadjuvant pembrolizumab for locally advanced HNSCC. Participants and Participants This retrospective cohort study at a single tertiary academic hospital included treatment-naive patients with locally advanced oral cavity squamous cell carcinoma that were undergoing surgical resection. Clinical Observance and Relevance This cohort examined surgical problems in patients treated with neoadjuvant pespirab in local regionally advanced OCSCC treated with neoadjuvant pesymuzumab, finding that the symptoms were similar to those in patients undergoing standard-of-care therapy.

Source link: https://doi.org/10.1001/jamaoto.2022.2291


Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy

Context. u2014 Neoadjuvant systemic therapy refers to the use of a systemic agent for malignancy prior to surgical intervention, and has recently emerged as an option for the majority of breast cancer patients requiring adjuvant systemic therapy. As a result, treated breast carcinomas have now become routine pathology specimens. The American Joint Committee on Cancer staging system acknowledges the challenges of staging breast carcinomas following neoadjuvant treatment and provides important data points, but does not currently provide concrete figures regarding residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based measure that measures treatment response as a continuous variable, based on residual tumor burden in the breast and lymph nodes.

Source link: https://doi.org/10.5858/arpa.2022-0021-ep


Cutaneous myeloid sarcoma following neoadjuvant chemotherapy for breast carcinoma

Myeloid sarcoma is a neoplasm composed of myeloid blasts that occur outside the bone marrow, most often found simultaneously or after a diagnosis of acute myeloid leukemia. De novo MS has been diagnosed in patients with a history of non-hematolymphoid neoplasms treated with systemic chemotherapy for the first time. MS may have occurred in this patient's case, and Chemotherapy drugs may have played a pathogenic role.

Source link: https://doi.org/10.18203/issn.2454-2156.intjscirep20222157


Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients

Abstract Introduction Less than 20% of patients with resectable oesophageal cancerocarcinoma have a pathological reaction after neoadjuvant chemotherapy. Drug-sensitive tumor cells respond to drug therapy, according to drug therapy, while resistant cells cause autophagy and can recover following drug withdrawal. Methods Oesophageal adenocarcinoma tumor tissue from Queens University Belfast's Northern Ireland Biobank was examined retrospectively. Tumours from 144 patients treated with platinum-based neoadjuvant chemotherapy followed by surgical resection were assembled into tissue microarrays for immunohistochemical analysis. Tumor recurrence is also associated with LC3B globular structures, which are also associated with tumour recurrence. When these markers were combined, it was found that patients with low/negative cleavage staining and high/positive staining for both types of LC3B had the lowest overall survival.

Source link: https://doi.org/10.1186/s12885-022-09981-8

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions